×
Acasti Pharma Receivables 2014-2024 | ACST
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Acasti Pharma receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Acasti Pharma Receivables 2014-2024 | ACST
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Acasti Pharma receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$20.1B
Dr Reddy's Laboratories (RDY)
$13.1B
BridgeBio Pharma (BBIO)
$5B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Supernus Pharmaceuticals (SUPN)
$1.8B
Taysha Gene Therapies (TSHA)
$449M
Personalis (PSNL)
$315M
Assembly Biosciences (ASMB)
$117M
Sol-Gel Technologies (SLGL)
$20M
Evoke Pharma (EVOK)
$4M
Teligent (TLGT)
$0M